Hospital 340B Diversion and Duplicate Discounts: What Audit Findings Can Prove

Hospital 340B diversion occurs when a hospital uses the program’s drug discount for someone who is not its eligible patient. A prescription from an ineligible site can enter the hospital’s discount account even when a contract pharmacy fills it. The pharmacy employee who knows why the system accepted that prescription may know more about the problem than the audit’s final sentence reveals.

For pharmacy, finance and compliance employees who suspect hospital fraud, the trail runs from the prescribing site to the discount, the bill and management’s response.

What Is Hospital 340B Diversion?

Hospital 340B diversion sends the discount to an ineligible patient. The manufacturer funds a discount the hospital was not entitled to claim. The Health Resources and Services Administration’s program requirements prohibit that transfer and require hospitals to keep their registration information current, including outpatient facilities and contract pharmacies.

Patient eligibility reaches beyond a name in a dispensing file. The Government Accountability Office’s account of HRSA guidance connects eligibility to the hospital maintaining the patient’s health care records and responsibility for the patient’s care. The healthcare services must also fit the basis on which the provider qualified for the program.

Contract pharmacy patient eligibility therefore depends on hospital records as well as the pharmacy’s dispensing record. The written contract identifies which hospital sites the pharmacy serves. Some agreements cover the parent hospital and its child sites, such as offsite clinics, together. Others cover individual sites. The prescribing location matters even when the same pharmacy fills prescriptions for all of them.

The Health Resources and Services Administration’s FY2025 audit findings show the problem in concrete terms. At Adventist Medical Center, the agency found discounted drugs dispensed by contract pharmacies against prescriptions originating at ineligible sites. At Anderson Regional Medical Center, it found the same prescription-origin problem in drugs dispensed by the provider itself. At Baptist Health Medical Center Heber Springs, it found a discounted drug dispensed to an inpatient. The agency listed repayment to manufacturers for those findings.

Where the Hospital Gets the Discount

Hospitals make money on 340B when reimbursement for an outpatient drug exceeds the discounted price they paid. The Government Accountability Office explains that eligible patients can have insurance and that the program gives providers discretion over the resulting revenue. Hospitals do not have to pass the savings on 340B discounted purchases to patients.

The discount can also arrive after the prescription. In its August 2026 description of replenishment, the Health Resources and Services Administration explains that a pharmacy dispenses from a common inventory. Software then decides which prescriptions qualify for 340B. When enough qualifying dispenses accumulate, the hospital buys replacement stock at the discount through its wholesaler account.

The eligibility decision in the software determines which dispenses earn discounted replacement stock. That is why dispensing records, the eligibility settings behind them and replenishment purchases belong in the same story. The Health Resources and Services Administration describes third-party administrators managing eligibility tracking, split-billing software and claims data. The hospital retains responsibility for its contract-pharmacy arrangements.

How Do Hospital 340B Duplicate Discounts Happen?

Hospital 340B duplicate Medicaid discounts happen when a manufacturer gives the purchase discount and also pays a Medicaid rebate for the same drug. The manufacturer gives two price reductions on the same drug.

The state needs to identify the discounted drugs before requesting rebates. Some states use a code on the drug claim and the Medicaid Exclusion File, which identifies providers using 340B drugs for Medicaid fee-for-service patients.

Managed-care prescriptions need separate coordination with the state. In its contract-pharmacy review, the Government Accountability Office found that HRSA checked the risk of duplicate discounts in fee-for-service Medicaid while leaving managed care outside that review. Its October 2025 testimony still identified that gap. A patient-eligibility review and a Medicaid rebate review examine different parts of the transaction.

At Adventist Medical Center, the Health Resources and Services Administration listed inaccurate or incomplete Medicaid Exclusion File information as a duplicate-discount finding and required manufacturer repayment.

What Makes a Hospital 340B Eligible?

A hospital’s eligibility starts with its category and organizational structure. For a disproportionate-share hospital, the Health Resources and Services Administration requires an adjustment percentage greater than 11.75% on its most recently filed cost report. A private nonprofit qualifying through a state or local government contract must agree to serve low-income people outside Medicare and Medicaid eligibility.

The contract’s dates matter. The Government Accountability Office’s October 2025 testimony reported that the Health Resources and Services Administration had revised draft audit procedures to check whether government contracts covered the entire period under review. But GAO still wanted proof that the agency had stopped accepting retroactive contract documentation. The question is whether the contract existed when the hospital claimed the discount.

A contract-pharmacy registration can have a similar gap behind it. At Baptist Memorial Hospital – Tipton, the Health Resources and Services Administration found a pharmacy still registered without a written contract in place and listed its termination from the program. The registration entry and the signed agreement tell different parts of the story.

A Closed Audit Can Still Leave the Correction Unchecked

340B audit closure depends heavily on the provider’s own account of corrective action. The Government Accountability Office’s October 23, 2025 testimony described an annual program of 200 covered-entity audits, including hospitals and federal grantees. Auditors examine a sample of prescriptions filled over six months. A provider with findings must assess the wider problem, describe the correction and address any repayment to manufacturers.

The testimony returned to a finding in the Government Accountability Office’s 2018 contract-pharmacy report:

The hospital gets to attest to its own correction. The Government Accountability Office also found that the Health Resources and Services Administration left providers to decide how far back to look for the same problem. That gives the scope of the hospital’s review real financial significance: which prescriptions it counted, which it left outside the review and what it repaid.

An employee may have seen the corrective-action response go out while the same dispensing practice continued. The attestation describes what the hospital said it fixed. Later dispensing and billing records can show what changed.

California’s Settlements Turned on the Billing Rate

MemorialCare and Pomona Valley settled allegations of charging Medi-Cal above the actual acquisition cost of discounted drugs. These hospital billing allegations followed a change in which price the hospitals could charge California’s Medicaid program.

A court had temporarily blocked California’s acquisition-cost billing requirement. After the court lifted that restriction, the hospitals allegedly continued billing their higher usual and customary costs. The drug’s purchase price had to reach the billing system. According to the Justice Department, that change did not happen.

Memorial Health Services, operating as MemorialCare Health System, agreed to pay $31,532,679 in a settlement announced November 2, 2020. The payment was one and a half times the alleged overbilling. The Justice Department put the billing period at December 2016 to October 2019. An internal audit led to a voluntary disclosure that October.

Pomona Valley’s settlement announcement on February 2, 2024 described nearly $2.1 million to resolve approximately $1.4 million in alleged overbilling. After an internal audit, the hospital disclosed the overbilling itself in 2021 and again in 2023.

Both accounts put the loss on the United States and California, which jointly fund Medi-Cal. For a billing employee, the recognizable issue is the price instruction that stayed in use after the payment rule changed.

The Revised Rebate Pilot Changes the Payment Sequence

The hospital 340B rebate pilot would change when participating manufacturers provide the discount for selected drugs. The Health Resources and Services Administration’s August 3, 2026 notice described a revised pilot using rebates in place of upfront discounts, with manufacturer plans intended to take effect January 1, 2027.

That notice also records that the court vacated, or threw out, the earlier pilot notices and manufacturer approvals. The revised notice ties rebate processing to claims data and requires pricing information hospitals can use for actual-acquisition-cost Medicaid billing. That brings the same acquisition-cost question into a different payment sequence.

What the Hospital Knew When It Kept Billing

Manufacturer repayment addresses the drug discount. A hospital False Claims Act case follows the government bill and what the hospital knew was wrong with it. The California allegations show the payment connection: the hospitals billed Medi-Cal above actual acquisition cost. The False Claims Act reaches knowingly false claims for government payment.

An HRSA hospital repayment finding puts management’s response to the underlying prescriptions in view. Internal responses can show who understood the problem. A billing instruction, an eligibility setting left in place or claims submitted after a corrective-action attestation can connect that knowledge to later transactions.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Happened After the Audit

If you know why ineligible prescriptions kept qualifying or why a hospital kept using the wrong billing rate, speak with our whistleblower experts about what happened inside the system. We connect your knowledge of the prescriptions, payments and decisions to your strongest hospital whistleblower case, and bring in 340B whistleblower lawyers who know hospital drug-pricing cases. We stay with you through the full case.